The Shuman Law Firm announces that it is investigating potential claims against certain officers and directors of BioScrip, Inc. (“BioScrip” or the “Company”) (Nasdaq: BIOS). BioScrip is a New York-based company that provides home infusion and other home care services, and pharmacy benefit management services in the United States.

The Firm’s investigation relates to a U.S. Department of Justice Press Release which disclosed that BioScrip has agreed to forfeit $15 million for the Company’s participation in a kickback scheme with Novartis Pharmaceuticals, Inc.

If you currently own BioScrip common stock and are interested in discussing your rights, or have information relating to this investigation, please contact Kip B. Shuman or Rusty E. Glenn toll-free at 866-569-4531 or email Mr. Shuman at kip@shumanlawfirm.com or email Mr. Glenn at rusty@shumanlawfirm.com.

The Shuman Law Firm represents investors throughout the nation, concentrating its practice in stockholder litigation.

The Shuman Law FirmKip B. Shuman, Esq., 866-569-4531 or 303-861-3003kip@shumanlawfirm.comRusty E. Glenn, Esq., 866-569-4531 or 303-861-3003rusty@shumanlawfirm.comFax: 303-536-7849www.shumanlawfirm.com

BioPlus Acquisition (NASDAQ:BIOS)
Graphique Historique de l'Action
De Juin 2024 à Juil 2024 Plus de graphiques de la Bourse BioPlus Acquisition
BioPlus Acquisition (NASDAQ:BIOS)
Graphique Historique de l'Action
De Juil 2023 à Juil 2024 Plus de graphiques de la Bourse BioPlus Acquisition